News
ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)
New Phase I research showcases NR supplementation significantly increased cerebral NAD levels, and decreased levels of inflammatory cytokines in Parkinson's disease (PD) patients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a...
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release...
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
Newly granted continuation patent provides additional intellectual property protection for ChromaDex's Niagen® (patented nicotinamide riboside) ingredient LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent,...
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
ChromaDex's research & development program reaches 100 published peer-reviewed studies on Niagen® and other ingredients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program's (CERP™) 100th published...
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
Researchers publish new clinical data on NR supplementation, marking the 18th clinical trial on ChromaDex's Niagen® ingredient LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented...
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
ChromaDex announces supply agreement with Designs for Health, offering new Niagen®-formulated products LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements...
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
Total company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen® net sales of $14.8 million, up 24% from the prior year quarter and gross margin of 61.1% for the quarter. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today...
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
New clinical research in ataxia-telangiectasia (AT) patients finds nicotinamide riboside (NR) improved Ataxia scores and increased antibody levels LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study...
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The financial results will be reported in a press release...
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
Elysium Health to pay ChromaDex approximately $2.25 to $2.50 million in damages plus interest for breach of contract New partnership with Sinopharm Xingsha and recent partnerships with Walmart, H&H Group, and Ro to support next phase of growth LOS ANGELES -...